TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: total score at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resuscitation requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RDS development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HBV-DNA decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average light increment sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Student performance on objective examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean KSKS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychiatric functioning improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of discontinuation due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of weight gain greater than 7% from baseline
Endpoint domain: Adverse events/effects
Primary endpoint: Weight loss of at least 5% of baseline weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rating scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hearing handicap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total colony counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of US vs VCF for PE prevention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean transthyretin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: risk of fibrosis worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of subcutaneous fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: efavirenz plasma exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central nervous system symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: swallow score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blunted GH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Drowsiness levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Women's past year experience of sexual IPV
Endpoint domain: Adverse events/effects
Primary endpoint: Women's depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reports of male partner controlling behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Day 28 recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median times to first recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-year recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of post-term pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Need for formal induction of labor
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Delays in access to anti-malarial treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Expenses related to patients' transfer to the health post
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Food intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appetites (hunger, fullness, desire to eat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: any unanticipated transitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting triacylglycerol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of sdLDLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Compliance to the prescribed exercise regimen
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer falls
Endpoint domain: Adverse events/effects
Primary endpoint: Health-related quality of life (HRQOLI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Choice of effective contraceptive method
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Optimum lengths of knee flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Optimum lengths of knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of diabetic retinopathy scores >40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: waist-to-hip ratio reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of spontaneous defibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of ventricular arrhythmia
Endpoint domain: Adverse events/effects
Primary endpoint: Patient willingness to receive the same sedation method in the future
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 20-m walk speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 400-m walk speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of relapse to MDD
Endpoint domain: Mortality/survival
Primary endpoint: change in brain tissue oxygen (Pbto2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: serum ionized calcium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary deoxypyridinoline (D‐Pyr) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum calcitriol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of periprocedural myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary blood volume index (PBVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: area under the plasma concentration‐time curve (AUC0‐t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: half‐life (t ½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of chronic periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in the number of regular users of BZD and RD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PI of cerebral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of complications
Endpoint domain: Adverse events/effects
Primary endpoint: non-fatal heart failure events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incontinent episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mIIQ scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of axilla fossa drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder range of motion at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk recall scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' perceived understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction with the IC process
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the concentration time curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancomycin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ALT normalization at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction of ALT levels from baseline to 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic upper gastrointestinal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decision Conflict Scale (DCS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oesophageal acid exposure normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean percentage acid reflux time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: High HDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total sleep-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical activity (active living habits)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: preoperative cervical dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary podocyte detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary albumin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expressions of CTGF, OPN, and TGFβ1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal hair count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: creatine kinase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strength recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of response (DoR) of pleural effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum VEGF level at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of non-contrast high-resolution T2WI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control at the end of follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum resistin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Confirmed abstinence at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased risk of pancreatic cancer
Endpoint domain: Mortality/survival
Primary endpoint: safety and efficacy of EQW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cavg0-24 serum testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of women screened
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cases of sore throat
Endpoint domain: Mortality/survival
Primary endpoint: Time to progression of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rise in GCS (Glasgow Coma Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in skin surface pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: outcome of treatment with escitalopram and nortriptyline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset time for complete motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Congruence between implicit and explicit negative mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discharge from the ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery in the ICU
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frankl scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Houpt scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pouch-anal functional score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum and resting pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin conductance response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvement in function of the paretic upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCS‐12 scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: neglect measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to run the TUG test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD symptoms moderation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OROS-MPH dose at endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transluminal flow characteristics (TFCs) of coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adult height data (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental effect on stature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of atopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: suppression of cough-related laryngeal sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean P2Y12 reaction units (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of nonresponders to clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acquisition of ureteroscopic skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective simulator based measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endourological global rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood loss of at least 500 ml or use of additional uterotonic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CGM adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric reduction of bone grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: log[dextromethorphan metabolic ratio (MR)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Control of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Allergic inflammation (ICAM-1 expression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 18-month weight losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular events (death, acute myocardial infarction, recurrence of myocardial infarction)
Endpoint domain: Mortality/survival
Primary endpoint: NSS score after amantadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of pain after amantadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of relief from pain after amantadine
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relapse rates during the maintenance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pregnancy wastage rate
Endpoint domain: Mortality/survival
Primary endpoint: 48-hour post application colony counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PDQ-39 total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean PASI change from baseline at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Physical Functioning of the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of wound infection and dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Oedematous status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breath H2 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: severity of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tolerance of higher transfusion volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-normalized clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of 50-100 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum EPO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Hb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall remission (OFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: head and neck cancer-specific problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: social eating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: feeling ill
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Primary clinical outcome measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged abstinence at 3-month assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: whole-body catabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: level of health complaints of the coach drivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relapse of calcium oxalate stones
Endpoint domain: Mortality/survival
Primary endpoint: Urinary calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Factor VII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum total ΔPCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum-free Δ%PCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of cough and dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual health knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sexual attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sexual self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MPA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary PK parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemoglobin A1c (HbA1c) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: central retinal thickness increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: symptomatic reherniation
Endpoint domain: Mortality/survival
Primary endpoint: reoperation
Endpoint domain: Mortality/survival
Primary endpoint: 26-week abstinence
Endpoint domain: Mortality/survival
Primary endpoint: composite clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the pre-delivery phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First turn of speech about bad news
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of assessment and supportive utterances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes